Noninvasive insulin delivery: The great potential of cell-penetrating peptides

Therapeutic Delivery

Volumn 4, Issue 3, 2013, Pages 315-326

  Kamei, Noriyasu ^a   Nielsen, Ebbe Juel Bech ^a,b   Khafagy, El Sayed ^c   Takeda Morishita, Mariko ^a  

^a KOBE GAKUIN UNIVERSITY   (Japan)

^b NOVO NORDISK A S   (Denmark)

^c Suez Canal University   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE DODECAMER; ARGININE OCTAMER; BETA INTERFERON; CELL PENETRATING PEPTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; INSULIN; PENETRATIN; PROTEIN ERNS; PROTEIN PRL4; PROTEIN PVEC; PROTEIN RRL HELIX; REV PROTEIN; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG SAFETY; FIRST PASS EFFECT; INTESTINE ABSORPTION; MOLECULAR INTERACTION; NON INVASIVE PROCEDURE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 84874584382     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.12.164     Document Type: Review

References (76)

1. Hirsch IB. Drug therapy: insulin analogues. N. Engl. J. Med. 352, 174-183 (2005).
2. Morishita M, Peppas NA. Is the oral route possible for peptide and protein drug delivery? Drug Discov. Today 11, 905-910 (2006).
3. Khafagy El-S, Morishita M, Onuki Y, Takayama K. Current challenges in non-invasive insulin delivery systems: a comparative review. Adv. Drug Deliv. Rev. 59, 1521-1546(2007).
4. Goldberg M, Gomez-Orellana I. Challenges for the oral delivery of macromolecules. Nat. Rev. Drug Discov. 2, 289-295 (2003).
5. Owens DR, Zinman B, Bolli G. Alternative routes of insulin delivery. Diabetic Med. 20, 886-898 (2003).
6. Scott-Moncrieff JC, Shao Z, Mitra AK. Enhancement of intestinal insulin absorption by bile salt-fatty acid mixed micelles in dogs. J. Pharm. Sci. 83, 1465-1469 (1994).
7. Morishita M, Morishita I, Takayama K, Machida Y, Nagai T. Site-dependent effect of aprotinin, sodium caprate, Na2EDTA and sodium glycocholate on intestinal absorption of insulin. Biol. Pharm. Bull. 16, 68-72 (1993).
8. Yamamoto A, Taniguchi T, Rikyuu K et al. Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats. Pharm. Res. 11, 1496-1500 (1994).
9. Takeuchi H, Yamamoto H, Niwa T, Hino T, Kawashima Y. Enteral absorption of insulin in rats from mucoadhesive chitosan-coated liposomes. Pharm. Res. 13, 896-901 (1996).
10. Morishita M, Goto T, Nakamura K, Lowman AM, Takayama K, Peppas NA. Novel oral insulin delivery systems based on complexation polymer hydrogels: Single and multiple administration studies in type 1 and 2 diabetic rats. J. Control. Release 110, 587-594 (2006).
11. Liu H, Tang R, Pan WS, Zhang Y, Liu H. Potential utility of various protease inhibitors for improving the intestinal absorption of insulin in rats. J. Pharm. Pharmacol. 55, 1523-1529 (2003).
12. Carino GP, Jacob JS, Mathiowitz E. Nanosphere based oral insulin delivery. J. Control. Release 65, 261-269 (2000).
13. Qi R, Ping QN. Gastrointestinal absorption enhancement of insulin by administration of enteric microspheres and SNAC to rats. J. Microencapsul. 21, 37-45 (2004).
14. Degim Z, Unal N, Essiz D, Abbasoglu U. The effect of various liposome formulations on insulin penetration across Caco-2 cell monolayer. Life Sci. 75, 2819-2827 (2004).
15. Matsuzawa A, Morishita M, Takayama K, Nagai T. Absorption of insulin using water-in-oil-in-water emulsion from an enteral loop in rats. Biol. Pharm. Bull. 18, 1718-1723 (1995).
16. Morishita M, Kajita M, Suzuki A et al. The dose-related hypoglycemic effects of insulin emulsions incorporating highly purified EPA and DHA. Int. J. Pharm. 201, 175-185 (2000).
17. Lawman A, Morishita M, Kajita M, Nagai T, Peppas N. Oral delivery of insulin using pH-responsive complexation gels. J. Pharm. Sci. 88, 933-937 (1999).
18. Morishita M, Goto T, Peppas NA et al. Mucosal insulin delivery systems based on complexation polymer hydrogels: effect of particle size on insulin enteral absorption. J. Control. Release 97, 115-124 (2004).
19. Mesiha M, Plakogiannis F, Vejosoth S. Enhanced oral absorption of insulin from desolvated fatty acid-sodium glycocholate emulsions. Int. J. Pharm. 111, 213-216 (1994).
20. Radwant MA, Aboul-Enein HY. The effect of oral absorption enhancers on the in vivo performance of insulin-loaded poly(ethylcyanoacrylate) nanospheres in diabetic rats. J. Microencapsul. 19, 225-235 (2002).
21. Kimura T, Sato K, Sugimoto K et al. Oral administration of insulin as poly(vinyl alcohol)-gel spheres in diabetic rats. Biol. Pharm. Bull. 19, 897-900 (1996).
22. Damge C, Vranckx H, Balschmidt P, Couvreur P. Poly(alkyl cyanoacrylate) nanospheres for oral administration of insulin. J. Pharm. Sci. 86, 1403-1409 (1997).
23. Marschutz MK, Caliceti P, Bernkop-Schnurch A. Design and in vivo evaluation of an oral delivery system for insulin. Pharm. Res. 17, 1468-1474 (2000).
24. Goldberg M, Gomez-Orellana I. Challenges for the oral delivery of macromolecules. Nat. Rev. Drug.Discov. 2, 289-295(2003).
25. Woodley JF. Enzymatic barriers for GI peptide and protein delivery. Crit. Rev. Ther. Drug. Carrier. Syst. 11, 61-95 (1994).
26. Chang LL, Bai JPF. Evidence for the existence of insulin-degrading enzyme on the brush-border membranes of rat enterocytes. Pharm. Res. 13, 801-803 (1996).
27. Fasano A. Novel approaches for oral delivery of macromolecules. J. Pharm. Sci. 87, 1351-1356 (1998).
28. Cano-Cebrián MJ, Zornoza T, Granero L, Polache A. Intestinal absorption enhancement via the paracellular route by fatty acids, chitosans and others: a target for drug delivery. Curr. Drug. Deliv. 2, 9-22 (2005).
29. Foerg C, Merkle HP. On the biomedical promise of cell penetrating peptides: limits versus prospects. J. Pharm. Sci. 97, 144-162 (2008).
30. Heitz F, Morris MC, Divita G. Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br. J. Pharmacol. 157, 195-206 (2009).
31. Fonseca SB, Pereira MP, Kelly SO. Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv. Drug Deliv. Rev. 61, 953-964 (2009).
32. Vives E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 272, 16010-16017 (1997).
33. Mitchell DJ, Kim DT, Steinman L, Fathman CG, Rothbard JB. Polyarginine enters cells more efficiently than other polycationic homopolymers. J. Pept. Res. 56, 318-325 (2000).
34. Futaki S, Suzuki T, Ohashi W et al. Arginine-rich peptides: an abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J. Biol. Chem. 276, 5836-5840 (2001).
35. Nakase I, Takeuchi T, Tanaka G, Futaki S. Methodological and cellular aspects that govern the internalization mechanisms of arginine-rich cell-penetrating peptides. Adv. Drug Deliv. Rev. 60, 598-607 (2008).
36. Derossi D, Joliot AH, Chassaing G, Prochiantz A. The third helix of the Antennapedia homeodomaintranslocates through biological membranes. J. Biol. Chem. 269, 10444-10450 (1994).
37. Derossi D, Calvet S, Trembleau A, Brunissen A, Chassaing G, Prochiantz A. Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J. Biol. Chem. 271, 18188-18193 (1996).
38. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285, 1569-1572 (1999).
39. Astriab-Fisher A, Sergueev D, Fisher M, Shaw BR, Juliano RL. Conjugates of antisense oligonucleotides with the TAT and antennapedia cell-penetrating peptides: effects on cellular uptake, binding to target sequences, and biologic actions. Pharm. Res. 19, 744-754 (2002).
40. Torchilin VP, Levchenko TS. TAT-liposomes: a novel intracellular drug carrier. Curr. Protein Pept. Sci. 4, 133-140 (2003).
41. Marty C, Meylan C, Schott H, Ballmer-Hofer K, Schwendener RA. Enhanced heparan sulfate proteoglycan-mediated uptake of cell-penetrating peptide-modified liposomes. Cell. Mol. Life Sci. 61, 1785-1794 (2004).
42. Gupta B, Levchenko TS, Torchilin VP. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv. Drug Deliv. Rev. 57, 637-651 (2005).
43. Futaki S. Oligoarginine vectors for intracellular delivery: design and cellular-uptake mechanisms. Biopolymers 84, 241-249 (2006).
44. Richard JP, Melikov K, Vives E et al. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J. Biol. Chem. 278, 585-590 (2003).
45. NakaseI, Niwa M, Takeuchi T et al. Cellular uptake of arginine-rich peptides: roles for macropinocytosis and actin rearrangement. Mol. Ther. 10, 1011-1022 (2004).
46. Console S, Marty C, Garcia-Echeverria C, Schwendener R, Ballmer-Hofer K. Antennapedia and HIV transactivator of transcription (TAT) "protein transduction domains" promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans. J. Biol. Chem. 278, 35109-35114 (2003).
47. Fittipaldi A, Ferrari A, Zoppe M et al. Cell membrane lipid rafts mediate caveolar endocytosis of HIV-1 Tat fusion proteins. J. Biol. Chem. 278, 34141-34149 (2003).
48. Wadia JS, Stan RV, Dowdy SF. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat. Med. 10, 310-315 (2004).
49. Richard JP, Melikov K, Brooks H, Prevot P, Lebleu B, Chernomordik LV. Cellular uptake of unconjugated TAT peptide involves clathrin-dependent endocytosis and heparan sulfate receptors. J. Biol. Chem. 280, 15300-15306 (2005).
50. Kaplan IM, Wadia JS, Dowdy SF. Cationic TAT peptide transduction domain enters cells by macropinocytosis. J. Control. Release 102, 247-253 (2005).
51. Jiao CY, Delaroche D, Burlina F, Alves ID, Chassaing G, Sagan S. Translocation and endocytosis for cell-penetrating peptide internalization. J. Biol. Chem. 284, 33957-33965 (2009).
52. Zaro JL, Rajapaksa TE, Okamoto CT, Shen WC. Membrane transduction of oligoarginine in HeLa cells is not mediated by macropinocytosis. Mol. Pharm. 3, 181-186 (2006).
53. Drin G, Cottin S, Blanc E, Rees AR, Temsamani J. Studies on the internalization mechanism of cationic cell-penetrating peptides. J. Biol. Chem. 278, 31192-31201 (2003) .
54. Duchardt F, Fotin-Mleczek M, Schwarz H, Fischer R, Brock R. A comprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic 8, 848-866 (2007).
55. Tunnemann G, Martin RM, Haupt S, Patsch C, Edenhofer F, Cardoso MC. Cargo-dependent mode of uptake and bioavailability of TAT-containing proteins and peptides in living cells. FASEB J. 20, 1775-1784 (2006).
56. Fretz MM, Penning NA, Al-Taei S et al. Temperature-, concentration-and cholesterol-dependent translocation of l-and d-octa-arginine across the plasma and nuclear membrane of CD34+ leukaemia cells. Biochem. J. 403, 335-342 (2007).
57. Ter-Avetisyan G, Tunnemann G, Nowak D et al. Cell entry of arginine-rich peptides is independent of endocytosis. J. Biol. Chem. 284, 3370-3378 (2009).
58. Kamei N, Morishita M, Eda Y, Ida N, Nishio R, Takayama K. Usefulness of cell-penetrating peptides to improve intestinal insulin absorption. J. Control. Release 132, 21-25 (2008).
59. Anderberg EK, Artursson P. Epithelial transport of drugs in cell culture. VIII: Effects of sodium dodecyl sulfate on cell membrane and tight junction permeability in human intestinal epithelial (Caco-2) cells. J. Pharm. Sci. 82, 392-398 (1993).
60. Uchiyama T, Sugiyama T, Quan YS et al. Enhanced permeability of insulin across the rat intestinal membrane by various absorption enhancers: their intestinal mucosal toxicity and absorption-enhancing mechanism of n-lauryl-beta-d-maltopyranoside. J. Pharm. Pharmacol. 51, 1241-1250 (1999).
61. Dimitrijevic D, Shaw AJ, Florence AT. Effects of some non-ionic surfactants on transepithelial permeability in Caco-2 cells. J. Pharm. Pharmacol. 52, 157-162 (2000).
62. Costantino HR, Illum L, Brandt G et al. Intranasal delivery: Physicochemical and therapeutic aspects. Int. J. Pharm. 337, 1-24 (2007).
63. Khafagy El-S, Morishita M, Isowa K, Imai J, Takayama K. Effect of cell-penetrating peptides on the nasal absorption of insulin. J. Control. Release 133, 103-108 (2009).
64. Yamamoto A, Hayakawa E, Lee VH. Insulin and proinsulin proteolysis in mucosal homogenates of the albino rabbit: implications in peptide delivery from nonoral routes. Life Sci. 47, 2465-2474 (1990).
65. Kamei N, Morishita M, Takayama K. Importance of intermolecular interaction on the improvement of intestinal therapeutic peptide/protein absorption using cell-penetrating peptides. J. Control. Release 136, 179-186 (2009).
66. Khafagy El-S, Morishita M, Takayama K. The role of intermolecular interactions with penetratin and its analogue on the enhancement of absorption of nasal therapeutic peptides. Int. J. Pharm. 388, 209-212 (2010).
67. Kamei N, Morishita M, Ehara J, Takayama K. Permeation characteristics of oligoarginine through intestinal epithelium and its usefulness for intestinal peptide drug delivery. J. Control. Release 131, 94-99 (2008).
68. Christiaens B, Grooten J, Reusens M et al. Membrane interaction and cellular internalization of penetratin peptides. Eur. J. Biochem. 271, 1187-1197 (2004).
69. Bellet-Amalric E, Blaudez D, Desbat B, Graner F, Gauthier F, Renault A. Interaction of the third helix of Antennapedia homeodomain and a phospholipid monolayer, studied by ellipsometry and PM-IRRAS at the air-water interface. Biochim. Biophys. Acta 1467, 131-143 (2000).
70. Letoha T, Gaal S, Somlai C, Czajlik A, Perczel A, Penke B. Membrane translocation of penetratin and its derivatives in different cell lines. J. Mol. Recognit. 16, 272-279 (2003).
71. Åmand HL, Fant K, Nordén B, Esbjörner EK. Stimulated endocytosis in penetratin uptake: effect of arginine and lysine. Biochem. Biophys. Res. Commun. 371, 621-625 (2008).
72. Khafagy El-S, Morishita M, Kamei N, Eda Y, Ikeno Y, Takayama K. Efficiency of cell-penetrating peptides on the nasal and intestinal absorption of therapeutic peptides and proteins. Int. J. Pharm. 381, 49-55 (2009).
73. Khafagy El-S, Morishita M, Ida N, Nishio R, Isowa K, Takayama K. Structural requirements of penetratin absorption enhancement efficiency for insulin delivery. J. Control. Release 143, 302-320(2010).
74. Kamei N, Kikuchi S, Takeda-Morishita M et al. Determination of the optimal cell-penetrating peptide sequence for intestinal insulin delivery based on molecular orbital analysis with self-organizing maps. J. Pharm. Sci. 102(2), 469-479 (2012).
75. Morishita M, Kamei N, Ehara J, Isowa K, Takayama K. A novel approach using functional peptides for efficient intestinal absorption of insulin. J. Control. Release 118, 177-184 (2007).
76. Kamei N, Morishita M, Kanayama Y et al. Molecular imaging analysis of intestinal insulin absorption boosted by cell-penetrating peptides by using positron emission tomography. J. Control. Release 146, 16-22 (2010).